N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=105 Pancreatic Juice Diagnosis From Duodenum
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
N/A N=340 Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
N/A N=174 TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Pancreatic Cancer · Pancreatitis · IPMN
Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
N/A N=341 Prevalence of Pancreatic Cysts During Routine Endoscopic Ultra Sound
Pancreatic Cysts
Primary: Prevalence of Pancreatic Cysts During Routine EUS — 46 participants found to have a cyst
N/A N=23 Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients
Pancreatic Cancer
Primary: S-MRCP and S-EUS Concordance
Phase 2 N=63 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
PDAC - Pancreatic Ductal Adenocarcinoma · FAP
Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants
N/A N=30 Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001
Phase 2 N=20 Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Pancreatic Mucinous-Cystic Neoplasm
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
N/A N=66 In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors
Pancreatic Cysts
Primary: Sensitivity — 59 percentage of participants
Phase 1 N=33 Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
Phase 2 N=48 A Phase II Study of Neoadjuvant FOLFIRINOX
Resectable Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 3 N=200 Standardization of Surgery on the Pancreatic Cancer
Pancreatic Cancer
Primary: Survival — 37; 31 participants
Phase 2 N=10 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
Phase 2 N=20 Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Radiographic Response (RR) — 9; 0; 9; 9 Participants
Early Phase 1 N=11 Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
Phase 2 N=54 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Phase 2 N=13 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Pancreatic Neuroendocrine Tumor G1 · Pancreatic Neuroendocrine Tumor G2 · Refractory Pancreatic Neuroendocrine Carcinoma
Primary: Overall Response Rate — 0 proportion of participants
Phase 2 N=59 Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
Pancreatic Cancer
Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants
Phase 2 N=83 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Phase 4 N=106 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Well-differentiated Pancreatic Neuroendocrine Tumor
Primary: Progression-Free Survival (PFS): Investigator Assessment — 13.2; 13.0 months
N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
Phase 4 N=15 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Pancreatic Cancer
Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…
Phase 3 N=284 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Pancreatic Cancer Non-resectable
Primary: Overall Survival — 17.25; 17.94 months — p=0.5487
Phase 2 N=22 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Multiple Endocrine Neoplasia Type 1 · Pancreatic Neuroendocrine Carcinoma
Primary: Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 9.5 percentage of participants
N/A N=1 Stereotactic Radiation to Decrease Pancreatic Secretions
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants